The effect of Metformin on endometrial tumor-regulatory genes and systemic metabolic parameters in polycystic ovarian syndrome-a proof-of-concept study

Mohamad Nasir Shafiee, Dahlia Abd Malik, Ryia Illani Mohd Yunos, William Atiomo, Mohd Hashim Omar, Nur Azurah Abdul Ghani, Ahmad Zailani Hatta, Claire Seedhouse, Caroline Chapman, Norfilza Mohd Mokhtar

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The aim of this proof-of-concept study was to determine the effects of three-month Metformin therapy on the expression of tumor-regulatory genes (p53, cyclin D2 and BCL-2) in the endometrium of women with polycystic ovary syndrome (PCOS). A total of 40 women, aged between 21 and 45 years with PCOS (Rotterdam criteria) were recruited. The participants were assessed at pre-and 3-month-post-Metformin therapy for the menstrual regularities, weight reduction, Ferriman Galway scores, fasting blood glucose (FBG), total cholesterol,LDL, HDL and p53, BCL-2 and cyclin D2 gene expression. Five participants conceived spontaneously after the initial recruitment. Majority (68%) resumed regular menstrual cycles after Metformin. There were significant reduction in BMI (p=0.001), weight (p=0.001) and Ferriman Galway scores (p=0.001). A significant improvement was seen in mean FBG (p=0.002), total cholesterol (p=0.001), LDL (p=0.003) and HDL cholesterol levels (p=0.015). Tumor suppressor gene (p53) was significantly up-regulated after Metformin (10 out of 14 women), with p value 0.016. BCL-2 and cyclin D2 (oncogenes) were slightly up-regulated without significant difference (p=0.119 and 0.155, respectively). In conclusion, Metformin therapy improved clinical and metabolic parameters in women with PCOS and up-regulated p53 tumor suppressor gene significantly. Further studies are however required to independently validate our findings.

Original languageEnglish
Pages (from-to)286-290
Number of pages5
JournalGynecological Endocrinology
Volume31
Issue number4
DOIs
Publication statusPublished - 1 Apr 2015

Fingerprint

Polycystic Ovary Syndrome
Metformin
Regulator Genes
Cyclin D2
Neoplasms
Tumor Suppressor Genes
HDL Cholesterol
Blood Glucose
Fasting
Menstrual Cycle
Endometrium
Oncogenes
LDL Cholesterol
Weight Loss
Therapeutics
Cholesterol
Gene Expression
Weights and Measures

Keywords

  • Endometrial cancer
  • Genes
  • Metformin
  • PCOS

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Obstetrics and Gynaecology

Cite this

The effect of Metformin on endometrial tumor-regulatory genes and systemic metabolic parameters in polycystic ovarian syndrome-a proof-of-concept study. / Shafiee, Mohamad Nasir; Malik, Dahlia Abd; Yunos, Ryia Illani Mohd; Atiomo, William; Omar, Mohd Hashim; Abdul Ghani, Nur Azurah; Hatta, Ahmad Zailani; Seedhouse, Claire; Chapman, Caroline; Mohd Mokhtar, Norfilza.

In: Gynecological Endocrinology, Vol. 31, No. 4, 01.04.2015, p. 286-290.

Research output: Contribution to journalArticle

@article{8a028dd7600944b4b4c35bba2b5541eb,
title = "The effect of Metformin on endometrial tumor-regulatory genes and systemic metabolic parameters in polycystic ovarian syndrome-a proof-of-concept study",
abstract = "The aim of this proof-of-concept study was to determine the effects of three-month Metformin therapy on the expression of tumor-regulatory genes (p53, cyclin D2 and BCL-2) in the endometrium of women with polycystic ovary syndrome (PCOS). A total of 40 women, aged between 21 and 45 years with PCOS (Rotterdam criteria) were recruited. The participants were assessed at pre-and 3-month-post-Metformin therapy for the menstrual regularities, weight reduction, Ferriman Galway scores, fasting blood glucose (FBG), total cholesterol,LDL, HDL and p53, BCL-2 and cyclin D2 gene expression. Five participants conceived spontaneously after the initial recruitment. Majority (68{\%}) resumed regular menstrual cycles after Metformin. There were significant reduction in BMI (p=0.001), weight (p=0.001) and Ferriman Galway scores (p=0.001). A significant improvement was seen in mean FBG (p=0.002), total cholesterol (p=0.001), LDL (p=0.003) and HDL cholesterol levels (p=0.015). Tumor suppressor gene (p53) was significantly up-regulated after Metformin (10 out of 14 women), with p value 0.016. BCL-2 and cyclin D2 (oncogenes) were slightly up-regulated without significant difference (p=0.119 and 0.155, respectively). In conclusion, Metformin therapy improved clinical and metabolic parameters in women with PCOS and up-regulated p53 tumor suppressor gene significantly. Further studies are however required to independently validate our findings.",
keywords = "Endometrial cancer, Genes, Metformin, PCOS",
author = "Shafiee, {Mohamad Nasir} and Malik, {Dahlia Abd} and Yunos, {Ryia Illani Mohd} and William Atiomo and Omar, {Mohd Hashim} and {Abdul Ghani}, {Nur Azurah} and Hatta, {Ahmad Zailani} and Claire Seedhouse and Caroline Chapman and {Mohd Mokhtar}, Norfilza",
year = "2015",
month = "4",
day = "1",
doi = "10.3109/09513590.2014.989982",
language = "English",
volume = "31",
pages = "286--290",
journal = "Gynecological Endocrinology",
issn = "0951-3590",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - The effect of Metformin on endometrial tumor-regulatory genes and systemic metabolic parameters in polycystic ovarian syndrome-a proof-of-concept study

AU - Shafiee, Mohamad Nasir

AU - Malik, Dahlia Abd

AU - Yunos, Ryia Illani Mohd

AU - Atiomo, William

AU - Omar, Mohd Hashim

AU - Abdul Ghani, Nur Azurah

AU - Hatta, Ahmad Zailani

AU - Seedhouse, Claire

AU - Chapman, Caroline

AU - Mohd Mokhtar, Norfilza

PY - 2015/4/1

Y1 - 2015/4/1

N2 - The aim of this proof-of-concept study was to determine the effects of three-month Metformin therapy on the expression of tumor-regulatory genes (p53, cyclin D2 and BCL-2) in the endometrium of women with polycystic ovary syndrome (PCOS). A total of 40 women, aged between 21 and 45 years with PCOS (Rotterdam criteria) were recruited. The participants were assessed at pre-and 3-month-post-Metformin therapy for the menstrual regularities, weight reduction, Ferriman Galway scores, fasting blood glucose (FBG), total cholesterol,LDL, HDL and p53, BCL-2 and cyclin D2 gene expression. Five participants conceived spontaneously after the initial recruitment. Majority (68%) resumed regular menstrual cycles after Metformin. There were significant reduction in BMI (p=0.001), weight (p=0.001) and Ferriman Galway scores (p=0.001). A significant improvement was seen in mean FBG (p=0.002), total cholesterol (p=0.001), LDL (p=0.003) and HDL cholesterol levels (p=0.015). Tumor suppressor gene (p53) was significantly up-regulated after Metformin (10 out of 14 women), with p value 0.016. BCL-2 and cyclin D2 (oncogenes) were slightly up-regulated without significant difference (p=0.119 and 0.155, respectively). In conclusion, Metformin therapy improved clinical and metabolic parameters in women with PCOS and up-regulated p53 tumor suppressor gene significantly. Further studies are however required to independently validate our findings.

AB - The aim of this proof-of-concept study was to determine the effects of three-month Metformin therapy on the expression of tumor-regulatory genes (p53, cyclin D2 and BCL-2) in the endometrium of women with polycystic ovary syndrome (PCOS). A total of 40 women, aged between 21 and 45 years with PCOS (Rotterdam criteria) were recruited. The participants were assessed at pre-and 3-month-post-Metformin therapy for the menstrual regularities, weight reduction, Ferriman Galway scores, fasting blood glucose (FBG), total cholesterol,LDL, HDL and p53, BCL-2 and cyclin D2 gene expression. Five participants conceived spontaneously after the initial recruitment. Majority (68%) resumed regular menstrual cycles after Metformin. There were significant reduction in BMI (p=0.001), weight (p=0.001) and Ferriman Galway scores (p=0.001). A significant improvement was seen in mean FBG (p=0.002), total cholesterol (p=0.001), LDL (p=0.003) and HDL cholesterol levels (p=0.015). Tumor suppressor gene (p53) was significantly up-regulated after Metformin (10 out of 14 women), with p value 0.016. BCL-2 and cyclin D2 (oncogenes) were slightly up-regulated without significant difference (p=0.119 and 0.155, respectively). In conclusion, Metformin therapy improved clinical and metabolic parameters in women with PCOS and up-regulated p53 tumor suppressor gene significantly. Further studies are however required to independently validate our findings.

KW - Endometrial cancer

KW - Genes

KW - Metformin

KW - PCOS

UR - http://www.scopus.com/inward/record.url?scp=84931071442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931071442&partnerID=8YFLogxK

U2 - 10.3109/09513590.2014.989982

DO - 10.3109/09513590.2014.989982

M3 - Article

C2 - 25495168

AN - SCOPUS:84931071442

VL - 31

SP - 286

EP - 290

JO - Gynecological Endocrinology

JF - Gynecological Endocrinology

SN - 0951-3590

IS - 4

ER -